PUBLISHER: The Business Research Company | PRODUCT CODE: 1763051
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763051
Adagen is a brand name for pegademase bovine, an enzyme replacement therapy used to treat severe combined immunodeficiency (SCID) caused by adenosine deaminase deficiency. It helps support immune function in individuals with SCID, reducing the risk of life-threatening infections by replenishing the missing enzyme necessary for proper immune system development.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main product forms of adagen are pre-filled syringes and vials. The pre-filled option provides a ready-to-use syringe or device, ensuring convenience and precise dosing for patients. Adagen is primarily used for clinical indications such as severe combined immunodeficiency (SCID) and other rare genetic disorders. It is utilized across various settings, including hospitals and healthcare institutions, specialty clinics, home healthcare services, and research institutions.
The adagen market research report is one of a series of new reports from The Business Research Company that provides adagen market statistics, including adagen industry global market size, regional shares, competitors with a adagen market share, detailed adagen market segments, market trends and opportunities, and any further data you may need to thrive in the adagen industry. This adagen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The adagen market size is expected to see strong growth in the next few years. It will grow to $123.6 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to ongoing innovation in drug delivery systems, growing healthcare infrastructure in emerging economies, increasing accessibility of enzyme replacement therapies, supportive reimbursement policies, and rising prevalence of genetic disorders. Major trends in the forecast period include the introduction of biosimilar enzyme replacement therapies, a focus on reducing production costs, increasing digitalization in healthcare supply chains, collaboration between biotech firms and academic institutions, and advances in long-acting formulations.
The increasing adoption of precision medicine is expected to significantly drive the growth of the adagen market. Precision medicine, which tailors medical treatments to individual genetic profiles, is gaining traction due to advancements in genomic technologies, biomarker availability, artificial intelligence integration, and the growing demand for targeted therapies. Adagen is directly aligned with this shift by providing targeted enzyme replacement therapy for patients with severe combined immunodeficiency (SCID) caused by adenosine deaminase deficiency. In 2023, the FDA approved 16 new personalized treatments for rare diseases, reflecting the growing adoption of precision medicine, which will continue to propel the adagen market.
The increasing diagnosis of rare diseases is driving the growth of the adagen market. Rare diseases, which affect fewer than 1 in 2,000 people, are being diagnosed more frequently due to advancements in genetic testing, greater awareness, and better healthcare infrastructure. Adagen contributes to the treatment of SCID, a rare genetic disorder, by offering enzyme replacement therapy, thus supporting early diagnosis and broader research into rare diseases. In the UK alone, over 3.5 million people are affected by rare diseases, which highlights the need for treatments like Adagen to address these conditions, further boosting market demand.
Rising healthcare expenditure is key factor contributing to the growth of the adagen market. As healthcare spending increases due to factors such as medical advancements, aging populations, and rising chronic diseases, the demand for specialized treatments like enzyme replacement therapies is also rising. Adagen's role in treating rare genetic disorders contributes to this rising healthcare expenditure, particularly as the U.S. pharmaceutical industry reached $550 billion in revenue in 2021, with projected spending expected to increase significantly in the coming years. Thus, rising healthcare expenditure supports the continued growth of the Adagen market.
Key player operating in the adagen market are Leadiant Biosciences Inc.
North America was the largest region in the adagen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adagen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the adagen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The adagen market consists of sales of single-use vials and ready-to-use syringes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Adagen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on adagen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for adagen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adagen market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.